RGLS - Regulus Therapeutics Inc.

NasdaqGM - NasdaqGM Delayed Price. Currency in USD
Income Statement
Balance Sheet
Cash Flow

Income Statement

All numbers in thousands
Total Revenue1,19420,7597,669
Cost of Revenue---
Gross Profit1,19420,7597,669
Operating Expenses
Research Development64,30556,38741,046
Selling General and Administrative18,39119,13011,533
Non Recurring---
Total Operating Expenses---
Operating Income or Loss-81,502-54,758-44,910
Income from Continuing Operations
Total Other Income/Expenses Net844-956-11,730
Earnings Before Interest and Taxes-80,658-55,714-56,640
Interest Expense1,1825239
Income Before Tax-81,840-55,766-56,679
Income Tax Expense-4-181
Minority Interest---
Net Income From Continuing Ops-81,836-55,748-56,680
Non-recurring Events
Discontinued Operations---
Extraordinary Items---
Effect Of Accounting Changes---
Other Items---
Net Income
Net Income-81,836-55,748-56,680
Preferred Stock And Other Adjustments---
Net Income Applicable To Common Shares-81,836-55,748-56,680